Fierce Biotech December 8, 2023
The medtech startup incubator Ajax Health has launched a new venture for developing pulsed field ablation treatments to zap the common irregular heart rhythm known as atrial fibrillation.
Cortex will start off with $90 million in funding commitments, led by KKR and Hellman & Friedman, with backing from other investors that include AI Life Sciences, an affiliate of Access Industries.
The company will also get a head start toward its goal of offering an integrated system that can help diagnose arrhythmias as well as treat them. Cortex will be led by CEO Duke Rohlen, who also serves as CEO of Ajax—and, fortuitously, as CEO of the Ajax outfit Ablacon, developer of an artificial intelligence-powered, FDA-cleared heart mapping system.